Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, MarcVolume:
59
Language:
english
Journal:
Diabetologia
DOI:
10.1007/s00125-015-3795-1
Date:
February, 2016
File:
PDF, 412 KB
english, 2016